PYPD
PolyPidNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$80.72M
P/E Ratio
—
EPS
$-2.09
Beta
1.46
52W High
$5.12
52W Low
$2.44
50-Day MA
$4.39
200-Day MA
$3.85
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About PolyPid
PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX) platform to address unmet medical needs. The company is headquartered in Petah Tikva, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-31.51M |
| Operating Margin | 0.00% |
| Return on Equity | -366.30% |
| Return on Assets | -86.70% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.60 |
| Price-to-Book | 7.62 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -0.36 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $19.08M |
| Float | $11.53M |
| % Insiders | 21.33% |
| % Institutions | 31.95% |
Analyst Ratings
Consensus ($12.25 target)
1
Strong Buy3
BuyData last updated: 4/9/2026